Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|March 2, 2014
- Pharmaceutical Technology-03-02-2014
- Volume 38
- Issue 3
ACQUITY QDa Detector Increases Productivity
Author(s)Melanie Sena
ACQUITY QDa Detector Increases Productivity
The new ACQUITY QDa Detector from Waters is compatible with ACQUITY UPLC, ACQUITY UPC2, HPLC, supercritical fluid chromatography, and LC-based purification systems. The on/off feature fully automates sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. The ACQUITY QDa Detector complements optical detection by confirming the identity of compounds with mass spectral information. Additionally, the ACQUITY QDa Detector extends the limits of sample detection for a chromatographic separation by quantifying compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection. The ACQUITY QDa Detector is available for separations systems running Empower 2 & 3 Chromatography Data System software.
Articles in this issue
over 12 years ago
Under New Ownershipover 12 years ago
Current issues with nanomedicinesover 12 years ago
Optimizing Solid Dosage Manufacturingover 12 years ago
European Union Packaging Safety Features Come into Effectover 12 years ago
Comparing Drug Layering and Direct Pelletization Processesover 12 years ago
7900 ICP-MS Increases Efficiencyover 12 years ago
Regulators Get Tough on Corruption in Chinaover 12 years ago
Best Practices in Adopting Single-Use Systemsover 12 years ago
Manufacturers Struggle with Breakthrough Drug DevelopmentRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.